Topical GHK-Cu closed diabetic ulcers faster in a 40-patient trial

What is GHK-Cu?

GHK-Cu is the copper(II) complex of GHK, a three-amino-acid fragment of human plasma proteins (glycyl-L-histidyl-L-lysine) that binds copper with high affinity.

GHK belongs to a class biologists call matrikines: small peptide fragments released from the extracellular matrix during tissue turnover or injury that act as local signals. Blood and tissue levels of free GHK are reported to fall with age and rise at sites of injury, the observation that first drew research attention to it.

How is GHK-Cu supposed to work?

In cell and animal studies, copper-bound GHK has been linked to collagen synthesis, modulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), angiogenesis, and antioxidant or anti-inflammatory signaling.

That mechanistic story is well documented in cell culture and rodent wound models, and a review by the peptide's original discoverer synthesizes it at length ^[3]. The review is a useful map of the biology. It is also written by the person with the deepest professional investment in the molecule's success, and it leans on preclinical data to make claims that sound more settled in humans than the clinical trial record supports.

Mechanism is not evidence of a human effect. It is a hypothesis that human trials then have to confirm or fail to confirm.

Does topical GHK-Cu heal wounds?

Topical GHK-Cu gel healed diabetic plantar ulcers better than vehicle in one 40-patient RCT, with 98.5% median closure versus 60.8% ^[1].

In Mulder's 1994 trial, treated wounds also closed roughly three times faster, and infection incidence fell from 34% to 7% ^[1]. That is a real, statistically significant, clinically meaningful result.

It is also one 40-patient trial. Topical wound-healing formulations are a different product entirely from the injectable protocols now circulating.

Does topical GHK-Cu reduce wrinkles?

Topical GHK-Cu has mixed wrinkle evidence: a laser-resurfacing trial found no objective benefit ^[2], and one small nano-lipid serum trial was positive.

Miller's 2006 RCT applied a copper tripeptide complex after CO2 laser resurfacing in 13 patients. It found no statistically significant improvement on the objective measures that matter most, erythema resolution and wrinkle scoring, even though patients reported liking the results more (P = .04) ^[2]. That is a null result on the endpoints an FDA reviewer would care about, dressed up by a positive satisfaction score.

Badenhorst's 2016 trial used a nano-lipid delivery system rather than a standard gel. It found a 55.8% reduction in wrinkle volume versus control and a 31.6% reduction versus an established comparator peptide (Matrixyl 3000) over 8 weeks. The result is encouraging and statistically significant, but it is a single small trial published in a low-impact open-access journal.

The negative laser-resurfacing trial used a different delivery vehicle from the nano-lipid trial. Formulation, delivery system, and copper concentration all vary between these three human trials, and that variation, not just sample size, is likely part of why the results diverge.

How strong is the evidence for GHK-Cu?

GHK-Cu's evidence rates grade C, moderate: real randomized trials in humans, not just cell dishes and mice, but few, small, and inconsistent ones.

Taken together, topical GHK-Cu has two positive RCTs and one negative RCT on objective endpoints, plus a review that reads more confident than the underlying trial record supports. Closing the gap would take a large registrational trial or a meta-analysis.

Has injectable GHK-Cu been tested in humans?

Injectable GHK-Cu has no published human trial for hair density or systemic anti-aging, and none of the cited studies tested subcutaneous or systemic GHK-Cu in people.

The hair-density and general anti-aging claims attached to injectable protocols are extrapolated from the same collagen- and angiogenesis-related mechanisms, observed in cell culture and animal tissue. No human RCT has confirmed them at any injectable dose. Injectable use is where the GHK-Cu evidence gap is largest and least acknowledged.

What GHK-Cu doses have trials tested?

GHK-Cu trials tested defined topical formulations, and no trial-derived dose, frequency, or duration exists for injectable use.

The topical trials that showed benefit used specific clinical formulations: Mulder's diabetic ulcer trial used a copper tripeptide gel applied to wound sites ^[1], and Badenhorst's wrinkle trial used a nano-lipid-carrier serum applied twice daily for 8 weeks. Results from one formulation do not automatically transfer to a different concentration, carrier, or application frequency, a detail most cosmetic marketing glosses over.

Forum injection conventions of 1 to 3 mg per day did not originate from a pharmacokinetic study. They were copied and refined informally across biohacking communities. That origin does not make them necessarily unsafe or ineffective, but anyone using them is operating without the human safety or efficacy data that exist for the topical form. Any injectable number is a community convention, not a clinical finding.

Is injectable GHK-Cu safe?

Daily systemic GHK-Cu injection adds copper load in a way that has not been characterized for long-term human safety.

Copper is an essential trace mineral with a narrow useful range. Past that range, free copper ions shift from participating in antioxidant enzyme systems to acting as pro-oxidants, generating reactive oxygen species rather than mitigating them. GHK-Cu's tight copper binding is part of what makes it interesting mechanistically. A separate article covers GHK-Cu injection and the body's copper regulation.

The FDA has separately flagged immunogenicity and aggregation risk specific to compounded injectable GHK-Cu, a regulatory concern distinct from the copper-load question that adds to it.

GHK-Cu also has a sourcing problem. The molecule is chemically prone to oxidation and degradation, particularly once reconstituted in solution, and improper storage or handling can alter it before it is ever used. A vial bought outside pharmacy-grade channels and reconstituted at home has no guarantee of matching the intact molecule tested in the RCTs; degraded GHK-Cu is not the same substance, and nothing in the forum literature accounts for this variable. A separate explainer covers how peptides degrade in solution.

What evidence is GHK-Cu still missing?

GHK-Cu has no published meta-analysis or large multi-site trial in any form.

• Independent replication. The topical cosmetic evidence rests on a small number of trials concentrated heavily in work connected to the peptide's original discoverer, which narrows independent replication.
• Injectable efficacy and safety. Injectable use in humans, for hair, systemic anti-aging, or general recovery, has no RCT data on efficacy, dosing, or long-term systemic safety.
• Copper accumulation. Copper accumulation risk with sustained subcutaneous dosing has not been formally studied in humans.
• Degraded product. The real-world effect of degraded or improperly stored peptide, as distinct from the pharmaceutical-grade compound used in trials, has not been characterized at all.